Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PPARA | Q07869 | 6/20 | 0.55 |
| ▸ | SYK | P43405 | 1/20 | 0.55 |
| ▸ | PPARG | P37231 | 3/20 | 0.53 |
| ▸ | CTSK | P43235 | 2/20 | 0.52 |
| ▸ | FOLH1 | Q04609 | 2/20 | 0.52 |
| ▸ | SIRT2 | Q8IXJ6 | 1/20 | 0.52 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.52 |
| ▸ | CTSL | P07711 | 1/20 | 0.51 |
| ▸ | CTSB | P07858 | 1/20 | 0.51 |
| ▸ | CTSS | P25774 | 1/20 | 0.51 |
| ▸ | ACE | P12821 | 1/20 | 0.51 |
| ▸ | ITGB3 | P05106 | 1/20 | 0.50 |
| ▸ | ITGA2B | P08514 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL42877 | 1.00 | PPARA (0.55) | PPARASYKPPARGCTSKFOLH1 | |
| SCHEMBL5971174 | 1.00 | PPARA (0.55) | PPARASYKPPARGCTSKFOLH1 | |
| SCHEMBL7821853 | 0.93 | FOLH1 (0.54) | PPARASYKPPARGFOLH1SIRT2 | |
| SCHEMBL8113270 | 0.93 | SIRT2 (0.55) | PPARASYKPPARGCTSKFOLH1 | |
| SCHEMBL13570899 | 0.93 | SYK (0.55) | PPARASYKPPARGCTSKCTSL | |
| SCHEMBL29336406 | 0.93 | SYK (0.55) | PPARASYKPPARGCTSKCTSL | |
| SCHEMBL29336412 | 0.93 | SYK (0.55) | PPARASYKPPARGCTSKCTSL | |
| SCHEMBL13570900 | 0.93 | SYK (0.55) | PPARASYKPPARGCTSKCTSL | |
| SCHEMBL9819558 | 0.93 | SYK (0.55) | PPARASYKPPARGCTSKCTSL | |
| SCHEMBL5972669 | 0.92 | MME (0.55) | PPARASYKCTSKFOLH1CTSL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 125 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4725560-A2 | ANTI-B7H3 ANTIBODIES FOR THE PREPARATION OF ANTIBODY DRUG CONJUGATES (ADCS) OF KSP INHIBITORS | Bayer Pharma Aktiengesellschaft (DE) | 2026-04-15 | — | — | EP | disclosed |
| WO-2025224463-A1 | DESMURAMYLPEPTIDE ANALOGUE MONOESTER | Imhotex Limited (GB) | 2025-10-30 | — | — | WO | disclosed |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | ARVINAS OPERATIONS INC (US) | 2025-10-16 | — | — | US | disclosed |
| US-12172981-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | ARVINAS OPERATIONS, INC. (US) | 2024-12-24 | — | — | US | disclosed |
| WO-2024224089-A1 | DESMURAMYLPEPTIDE MONOESTERS AS NOD2 AGONISTS AND USE THEREOF | Imhotex Limited (GB) | 2024-10-31 | — | — | WO | disclosed |
| CN-118834201-A | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-10-25 | — | — | CN | disclosed |
| EP-4425181-A1 | COMPOSITION FOR DETECTING OR MEASURING ANALYTE | Bertis Inc (KR) | 2024-09-04 | — | — | EP | disclosed |
| US-12059472-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | BAYER AKTIENGESELLSCHAFT (DE) | 2024-08-13 | — | — | US | disclosed |
| CN-110291087-B | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degrading agents | 阿尔维纳斯运营股份有限公司 | 2024-07-09 | — | — | CN | disclosed |
| EP-4361141-A1 | PROTEIN DEGRADATION AGENT | Suzhou Kintor Pharmaceuticals, Inc. (CN) | 2024-05-01 | — | — | EP | disclosed |
| EP-1340756-A1 | NOVEL BETA-LACTAM COMPOUNDS AND PROECSS FOR PRODUCING THE SAME | SUMITOMO PHARMACEUTICALS COMPANY, LIMITED (JP) | 2003-09-03 | — | — | EP | disclosed |
| WO-2003031407-A2 | β-LACTAMYL VASOPRESSIN VlaANTAGONISTS | SERENIX PHARMACEUTICALS, LLC (US) | 2003-04-17 | — | — | WO | disclosed |
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | BIOGEN IDEC INTERNATIONAL HOLDING LTD. (BM) | 2003-04-03 | — | — | US | disclosed |
| US-6423688-B1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | ATHENA NEUROSCIENCES, INC. | 2002-07-23 | — | — | US | disclosed |
| EP-1001971-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | Elan Pharmaceuticals, Inc. (US) | 2000-05-24 | — | — | EP | disclosed |
| WO-1999006432-A1 | DIPEPTIDE AND RELATED COMPOUNDS WHICH INHIBIT LEUKOCYTE ADHESION MEDIATED BY VLA-4 | ELAN PHARMACEUTICALS, INC. (US) | 1999-02-11 | — | — | WO | disclosed |
| US-5747499-A | CYCLOPENTAQUINAZOLINE COMPOUNDS CYCLOPENTAQUINAZOLINE COMPOUNDS | BRITISH TECHNOLOGY GROUP LIMITED (GB) | 1998-05-05 | — | — | US | disclosed |
| US-5552431-A | ANTICOAGULANTS | G. D. SEARLE & CO. (US) | 1996-09-03 | — | — | US | disclosed |
| US-5424334-A | Peptide mimetic compounds useful as platelet aggregation inhibitors | G. D. SEARLE & CO. (US) | 1995-06-13 | — | — | US | disclosed |
| WO-1993012074-A1 | PEPTIDE MIMETIC COMPOUNDS USEFUL AS PLATELET AGGREGATION INHIBITORS | G.D. SEARLE & CO. (US) | 1993-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12059472-B2 | Prodrugs of cytotoxic active agents having enzymatically cleavable groups | LGMN, BUB1B, KIF15 | PPARA 4562/4885SYK 2968/4885PPARG 4639/4885 |
| US-12172981-B2 | Tetrahydronaphthalene and tetrahydroisoquinoline derivatives as estrogen receptor degraders | MDM2, CRBN, VHL | PPARA 2293/4885SYK 4256/4885PPARG 2173/4885 |
| US-20250320195-A1 | TETRAHYDRONAPHTHALENE AND TETRAHYDROISOQUINOLINE DERIVATIVES AS ESTROGEN RECEPTOR DEGRADERS | MDM2, CRBN, VHL | PPARA 2293/4885SYK 4256/4885PPARG 2173/4885 |
| US-20030065185-A1 | Dipeptide and related compounds which inhibit leukocyte adhesion mediated by VLA-4 | VCAM1, ICAM1, IL4I1 | PPARA 1713/4885SYK 1621/4885PPARG 4006/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.